Swedish Orphan Biovitrum AB (publ) (SOBI.ST) Stock

SOBI.ST logo

Swedish Orphan Biovitrum AB (publ)

SOBI.STSweden
Healthcare

Company profile

Swedish Orphan Biovitrum AB (publ) reported revenue of 28.24 billion SEK for fiscal year 2025, up 8.5% from fiscal year 2024, and net income of 478.00 million SEK. That is a net profit margin of 1.7% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 7.18 billion SEK, up 11.1% from a year before. Its largest business segment, Haematology, brought in 68% of segment revenue in fiscal year 2025; United States was the largest region with 32%. In Q1 2026 it reported net income of 1.32 billion SEK, against net income of 875.00 million SEK a year earlier. Our analysis of its filings shows revenue growing from 22.12 billion SEK in fiscal year 2023 to 28.24 billion SEK in fiscal year 2025, 13.0% a year on average. Swedish Orphan Biovitrum AB (publ) reports about 2,207 full-time employees.

What stands out

  • Net income fell 87.7% in fiscal year 2025, from 3.89 billion SEK in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company is in strategic partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Largest shareholders

  • Investor AB (Investment Company)34.38%
  • Astrazeneca PLC9.80%
  • Fjärde AP-fonden5.81%
  • Swedish Orphan Biovitrum Ab3.51%
  • Nordea Investment Management AB1.32%

Share of the company, as of May 18, 2026

Leadership

  • Guido Oelkers Ph.D. — CEO & President, 60
  • Henrik Stenqvist M.Sc. — Chief Financial Officer, 58
  • Daniel Rankin — Chief Business Officer, 45
  • Gerard Tobin — Head of Investor Relations
  • Torbjörn Hallberg — General Counsel & Head of Legal Affairs, 56

How much revenue does Swedish Orphan Biovitrum AB (publ) make?

Swedish Orphan Biovitrum AB (publ) reported 28.24 billion SEK in revenue for fiscal year 2025, up 8.5% from 26.03 billion SEK in fiscal year 2024. In Q1 2026 revenue was 7.18 billion SEK.

What is Swedish Orphan Biovitrum AB (publ)'s largest business segment?

Haematology, with 19.12 billion SEK or 68% of segment revenue in fiscal year 2025. Next: Immunology (28%) and Specialty Care (5%).

Where does Swedish Orphan Biovitrum AB (publ) make most of its revenue?

United States: 32% of revenue by region in fiscal year 2025, followed by Europe (27%).

Has Swedish Orphan Biovitrum AB (publ) made a profit in recent years?

Net income by fiscal year: FY2021, 2.68 billion SEK; FY2022, 2.64 billion SEK; FY2023, 2.41 billion SEK; FY2024, 3.89 billion SEK; FY2025, 478.00 million SEK. It was profitable in each of these years.

How has Swedish Orphan Biovitrum AB (publ)'s revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 15.53 billion SEK; FY2022, 18.79 billion SEK; FY2023, 22.12 billion SEK; FY2024, 26.03 billion SEK; FY2025, 28.24 billion SEK.

Company Information

SectorHealthcare
IndustryBlood Disorder Treatment Drugs
Employees2,207
Founded1988
IPO DateSep 15, 2006
IPO StatusPublic
HeadquartersStockholm, Sweden
FoundersBo Jesper Hansen, Rishu Sood
ExchangeStockholm
TimezoneEurope/Stockholm (CET)

Contact & Links

Address
Norra Stationsgatan 93A, Stockholm
Phone
46 86 97 20 00
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Swedish Orphan Biovitrum AB (publ) (SOBI.ST)”, data as of May 18, 2026, https://dataporium.tech/stocks/SOBI.ST

LinkedInLinkedInXXYouTubeYouTube